Clinical Cases
Real-World Observations
The records below come from anonymised follow-up data collected with partner medical institutions, spanning eight different lung conditions.
These cases are anonymized individual observations, shared for information only. Age, disease course, concurrent medication and lifestyle all differ between patients, so outcomes vary widely: the changes recorded here are not a promise that every user will see the same result, and they do not constitute a claim of efficacy. JuvGuard is a health support product rather than a medicine, and it is not a substitute for prescribed treatment or a physician's advice.
Lung Function and Imaging Both Improved
This patient had lived with idiopathic pulmonary fibrosis for three years and became noticeably breathless after about 100 m on flat ground. Continuing his existing antifibrotic medication, he completed a 12-week course of nebulized exosome therapy. Forced vital capacity rose from 58% to 71% of predicted and six-minute walk distance improved by 42 m, while follow-up HRCT showed a smaller extent of fibrotic change than at baseline. No serious adverse events were recorded during the course.
Ground-Glass Nodule Shrinks Under Follow-Up
A 12 mm mixed ground-glass nodule in the right upper lobe was picked up on a health check, and the patient chose radiological surveillance first. He received nebulized exosome therapy during the 24-week observation window; the final CT measured the nodule at approximately 4 mm with better-defined margins. No biopsy or surgery was performed during follow-up, and he continues scheduled imaging as advised.
Lung Function Recovers After Viral Pneumonia
After severe COVID-19 she was left with ground-glass and consolidative changes in both lungs and felt short of breath even at rest on discharge. Eight weeks of nebulized exosome therapy was followed by a rise in forced vital capacity from 58% to 72% and an increase in six-minute walk distance from 290 m to 368 m, with repeat CT reporting substantial absorption of the ground-glass opacities. She described markedly better tolerance for stairs and household tasks.
Fewer Flare-Ups Over the Following Year
With a 40 pack-year smoking history, he had experienced three exacerbations in the preceding year. Across 16 weeks of nebulized exosome therapy alongside his maintenance inhalers, FEV1 rose from 45% to 58% of predicted and his CAT symptom score fell from 22 to 14. Only one exacerbation occurred over the following 12 months, with no further hospital admission.
Functional Change After Long-Term Dust Exposure
After 18 years of stone cutting, his cough and exertional breathlessness had worsened over the previous two years. Sixteen weeks of nebulized exosome therapy was followed by an increase in forced vital capacity from 61% to 69% and in six-minute walk distance from 320 m to 385 m. He reported less night-time coughing and easier morning sputum clearance, and continued the recommended occupational protection and dust avoidance.
Less Sputum, Fewer Infections
She had previously suffered two to three infective exacerbations a year with a heavy daily sputum load. After 12 weeks of nebulized exosome therapy combined with continued airway clearance physiotherapy, FEV1 rose from 52% to 60% of predicted and average daily sputum production fell from about 45 mL to about 20 mL. Only one exacerbation occurred during follow-up, with fewer days on antibiotics than the year before.
Imaging Stabilises, Exercise Tolerance Improves
Earlier imaging had shown fibrotic lesions progressing year by year. After 20 weeks of nebulized exosome therapy, forced vital capacity rose from 63% to 70%, diffusing capacity for carbon monoxide from 52% to 58%, and six-minute walk distance by roughly 50 m. Repeat imaging showed no new lesions and was reported as comparable with the previous study, appearing stable.
Fewer Infections, Fewer Hospital Days
An older adult who had previously needed antibiotics for four to five chest infections each year. Over the 12 months following a 12-week course of nebulized exosome therapy, two infectious episodes were recorded and hospital days fell from 21 to 6, with C-reactive protein returning to the normal range between episodes. She continued the recommended influenza and pneumococcal vaccination schedule.
Figures in these records describe individual cases, not the statistical results of a clinical trial; an individual's outcome may be better, worse, or unchanged.
JuvGuard is a health support product, not a pharmaceutical, and it does not replace medication prescribed by a physician or any medical procedure. The anonymised cases above are individual observations only: they are not a promise of therapeutic effect or of cure, and they should not be used as a reason to change or stop prescribed treatment.
To purchase, contact a sales consultant
WhatsApp & phone: +852 6746 9492
You can also write to us at info@juvguard.com, or discuss it with your own physician first.